Argenx price target raised to $540 from $480 at Truist

Truist raised the firm’s price target on Argenx to $540 from $480 and keeps a Buy rating on the shares. Based on encouraging data, the firm is introduce Sjogren’s disease contribution to its sum-of-parts valuation of Argenx while also increasing the tech value based on the company’s “impressive showing” at a recent R&D event, which highlighted “Vision 2030” with the goals of 5 new molecules, 10 indications and 50K on treatment by 2030, the analyst tells investors in a research note.